36 results about "Serum creatinine level" patented technology

Compositions comprising a plurality of yeast cells, wherein said plurality of yeast cells are characterized by their ability to ameliorate renal failure (e.g., improved diuretic effect and / or lowering blood urea nitrogen, proteinuria, and / or serum creatinine levels) in a subject as a result of having been cultured in the presence of an alternating electric field having a specific frequency and a specific field strength. Also included are methods of making and using such compositions.

The invention provides application of brown algae oligosaccharide or pharmaceutically acceptable salt thereof in preparation of a medicine for treating acute kidney injury, wherein the brown algae oligosaccharide is brown algae disaccharide, brown algae triose and / or brown algae tetraose. The invention also provides application of the brown algae oligosaccharide or the pharmaceutically acceptable salt thereof in preparation of medicines for preventing acute kidney injury from being converted into chronic kidney diseases. After the brown algae oligosaccharide is used for treating an animal with acute kidney injury, the serum creatinine level is obviously reduced, the urine concentration function of the kidney is obviously recovered, the levels of renal tubular injury factors (KIM-1 and NGAL) are obviously reduced, the expression of inflammatory factors is obviously reduced, the pathological change of the kidney is obviously improved, and the treatment effect is enhanced along with the increase of the dosage. Therefore, the brown algae oligosaccharide disclosed by the invention has a relatively strong effect of treating the acute kidney injury. In addition, when acute kidney injury occurs, the brown algae oligosaccharide disclosed by the invention can be used for protecting kidney functions and preventing the acute kidney injury from being converted into chronic kidney diseases.

The present invention relates to a new use of citral for manufacturing a medicament for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that citral is effective in alleviating symptoms of FSGS, including reducing glomerular epithelial hyperplasia lesions (EPHLs), peri-glomerular inflammation or glomerular hyalinosis or sclerosis, and also reducing proteinuria or hematuria or lowering serum urea nitrogen level or serum creatinine level in the subject.

The present invention provides one kind of Chinese medicine for treating chronic kidney function failure is prepared with Chinese medicinal materials, including ginseng, astragalus root, white atractylodes rhizome, Chuanxiong rhizome, leech, etc. The medicine has high curative effect, can improve clinical symptoms, reduce urea nitrogen in blood, lower creatinine level, reduce exhausted urine protein, protect kidney function, promote the synthesis of plasma protein, raise plasma protein density, improve body's nutrient state and produce many other positive effects. It is safe clinically and low in production cost.

The present invention addresses the problem of identifying a biomarker of renal failure, said biomarker being available from urine or blood, and fluctuating from an early stage than glomerular filtration rate and serum creatinine level, and thus developing a technique for diagnosing early stage kidney failure. A method for analyzing the blood, plasma, serum or urine of a renal failure suspected subject comprises a step of measuring the concentration of a pair of D-form and L-form of at least one amino acid selected from the amino acid group consisting of [D-serine] and [L-serine], etc., contained in the blood, plasma, serum or urine of the subject, and calculating, as an pathological index of the subject, the ratio of the D-form concentration to the L-form concentration or the percentage of the D-form concentration relative to the total concentration of the D-form and L-form.

The invention belongs to the field of medicine, and particularly relates to a drug composition for treating diabetic nephropathy, a preparation method and uses thereof. The technical problem solved by the present invention is to provide a completely-new drug composition for treating diabetic nephropathy. According to the drug composition of the present invention, caulis sinomenii, astragalus complanatus, milkvetch root, coptis chinensis and safflower are adopted as main bulk drugs to achieve the diabetic nephropathy treating purpose; and rosa laevigata michx and euryale ferox can further be added so as to further improve the treatment effect of the drug composition. According to the present invention, the most typical symptom of the diabetic nephropathy is nodular glomerulosclerosis and mainly the excretion amount of the urinary albumin is adopted as the diagnostic indicator, and after patients take the drug composition, the proteinuria excretion is significantly reduced, the 24 h urine total protein level and the urinary albumin excretion rate are reduced, the urinary albumin / creatinine ratio is reduced, the serum creatinine level is lowered, the life quality of patients is significantly improved, and the progress of the diabetic nephropathy disease is delayed.

This invention comprises a chlorophyllin composition and method of administering the same for using the same for treatment of kidney disease patients to achieve decrease in serum creatinine level. The chlorophyllin composition and its method of administration is also for concurrent increase in blood hemoglobin level. The Chlorophyllin is selected from the group consisting of sodium copper chlorophyllin, Potassium copper chlorophyllin, Potassium Iron chlorophyllin and other metal containing chlorophyllin / s. To the chlorophyllin composition are added additives, optionally, (a) a diluent, excipient or a carrier, and optionally (b) the chlorophyllin composition is administered, either concurrently, sequentially or in any other order, with other ingredients / compositions supportive for kidney function. The dosage form of composition comprises a liquid, powder, tablet and a capsule. A kit is also provided comprising the chlorophyllin composition and the additional ingredients. The other ingredients comprise amino acids taken individually or as a mixture, protein hydrolysate, proteins or protein concentrates, vitamins and minerals.